Celtium

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celtium

What is Celtium?

Celtium is a prescription medication whose active component is Escitalopram, a synthetic compound classified within the antidepressant group known as Selective Serotonin Reuptake Inhibitors (SSRIs). The drug's general purpose is to support the brain's internal systems for mood stabilization by moderating the activity of key chemical messengers, a process recognized for helping to manage symptoms of severe emotional discomfort.

Defining the Antidepressant Type and Identity

The identity of Celtium is defined by its core substance, Escitalopram, which operates as a highly selective SSRI. This medication is the pure (S)-enantiomer of the older compound citalopram, representing a chemical refinement that provides a targeted action on the central nervous system. This specific formulation is characterized by minimal binding affinity for numerous off-target receptors, a pharmacological trait that contributes to its specific profile among related medications.

Composition and Pharmaceutical Forms

Celtium is a single active ingredient product, containing Escitalopram (typically as the oxalate salt), and is manufactured for oral administration across its various preparations. Its presentation includes both coated tablets and an oral solution or liquid drops, which offers administrative flexibility. Celtium is available strictly on a prescription-only basis, as is standard for potent antidepressant therapy.

How Celtium’s Action Relates to its General Purpose

The overall purpose of Celtium is linked to its SSRI mechanism: to increase the availability of the neurotransmitter serotonin. By selectively blocking the reuptake process, the medication allows serotonin to remain active for longer periods in the spaces between nerve cells. This action supports communication within neural pathways, promoting a more stable and regulated emotional state.

Regulatory References

  1. NIH: PMC1413963

What side effects are possible with Celtium?

Possible Side Effects and Safety Information for Celtium

Officially Documented Serious Warnings

Regulatory agencies require that Celtium carry a boxed warning due to an increased risk of suicidal thoughts and behaviors in adolescents and young adults (up to age 24) compared to placebo, especially during initial therapy or dose adjustments. Close monitoring for clinical worsening and behavioral changes is mandatory.

Other serious risks include Serotonin Syndrome, a potentially life-threatening condition associated with confusion, agitation, high fever, and muscle rigidity, particularly when taken with other serotonergic agents. QT interval prolongation (an abnormality in heart rhythm) is also documented, which can lead to ventricular tachycardia and sudden death; maximum dose limits are imposed, particularly for older adults (60 years and over) or those with hepatic impairment, due to this dose-dependent cardiac risk.

Common Adverse Reactions

The most commonly observed adverse reactions (defined in clinical trials as occurring in 5% or more of patients and at least twice the rate of placebo) are primarily related to the nervous system and reproductive systems. These include nausea, insomnia, increased sweating (hyperhidrosis), somnolence, and various forms of sexual dysfunction (e.g., ejaculatory delay, decreased libido, or anorgasmia).

Safety Restrictions and Other Considerations

Celtium is contraindicated in patients taking Monoamine Oxidase Inhibitors (MAOIs), requiring a 14-day washout period between treatments. It is also contraindicated with pimozide. Safety-related precautions include the potential for activation of mania or hypomania in patients with undiagnosed bipolar disorder, an increased risk of bleeding (especially when co-administered with NSAIDs or anticoagulants), and the occurrence of hyponatremia (low blood sodium). Abrupt discontinuation should be avoided due to the risk of a discontinuation syndrome, and a gradual dose reduction is recommended whenever possible.

Overdose and Emergency Response

Overdose and when to seek help

This information reflects the officially documented descriptions of Escitalopram (Celtium) overdose based on government regulatory guidance.


Documented Manifestations and Severe Outcomes

An overdose is associated with documented effects on the Central Nervous System (CNS) and Cardiovascular System. CNS effects include Dizziness, Somnolence, Agitation, and severe outcomes such as Convulsions and Coma. Cardiovascular manifestations include Hypotension, Sinus Tachycardia, and documented ECG changes. Severe risks listed in regulatory documents include Serotonin Syndrome, QT prolongation, and the potential for a fatal outcome.


Emergency Action Required

Any suspected or confirmed overdose requires that individuals seek immediate medical attention. Regulatory instructions mandate contacting emergency services for assessment and hospital evaluation. Management is strictly symptomatic and supportive, as no specific antidote is known for Escitalopram toxicity. Official guidance requires continuous cardiac monitoring and stabilization of vital signs due to the risk of life-threatening cardiac dysrhythmias. Procedures such as Gastric Lavage or Activated Charcoal may be considered based on the context of the ingestion.


Population Considerations

Official labeling notes that older patients may be at increased risk of Hyponatremia (low sodium levels) as a potential complication in overdose scenarios.

Therapeutic Uses of Celtium

Quick Facts About Celtium

  • Major Depressive Disorder (MDD): Indicated for the management and stabilization of MDD in adult and adolescent patients.
  • Generalized Anxiety Disorder (GAD): Authorized for the acute treatment of GAD in adults and is considered a support for patient health in this domain.

Celtium is a therapeutic compound indicated for the clinical management of certain mood disorders. Its use is authorized for treating Major Depressive Disorder (MDD), including both the initial acute phase of treatment and long-term maintenance in adults and adolescents aged 12 and older. The medication is also utilized in the acute treatment of Generalized Anxiety Disorder (GAD) for adult patients.

Celtium is utilized to support the health and well-being of individuals diagnosed with these conditions. For instance, in MDD, it may contribute to a reduction in symptom severity and assists in maintaining stability over time. For GAD, the treatment is intended to help manage the condition and may improve daily functioning. Additional investigational uses of the compound are being studied for other related conditions. Always consult a qualified healthcare provider for guidance on appropriate treatment and dosage.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Celtium's official regulatory documentation strictly defines the populations eligible for use. The medication is contraindicated and must not be used by patients with a known hypersensitivity to escitalopram, citalopram, or any excipients. Use is also strictly prohibited with certain medications, including Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Linezolid, and in patients with known QT-interval prolongation or congenital long QT syndrome.

Age-Based Rules and Restrictions

Use is established for adults (18+), adolescents (12–17) for Major Depressive Disorder (MDD), and children (7–17) for Generalized Anxiety Disorder (GAD). Conversely, safety and effectiveness are not established for MDD in children younger than 12 or for GAD in children younger than 7.

Conditional Use Populations

Use requires caution and a restricted dose is recommended for special populations, including geriatric patients (65 years and older) and those with hepatic impairment (liver disease). Conditional use is also advised for patients with a history of seizures or mania/hypomania. During pregnancy, use is restricted to cases where the potential benefit officially justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Celtium Interactions with other medicines and products

The official regulatory profile identifies several types of clinically significant interactions with Celtium, primarily relating to its effects on serotonin, cardiac rhythm, and metabolic clearance.

Interaction Classification Primary Restriction or Constraint
Contraindicated Combinations Co-administration is prohibited with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, due to the high risk of Serotonin Syndrome. Concomitant use with Pimozide and other agents known to prolong the QTc interval is also contraindicated.
Exposure-Modifying Agents Strong inhibitors of CYP2C19 (e.g., cimetidine) can substantially increase Celtium plasma exposure ( AUC). This pharmacokinetic interaction requires specific patient-population and concomitant-drug considerations as noted in the label.
Pharmacodynamic Interactions Combining Celtium with other serotonergic medicines (e.g., triptans, lithium, tramadol) necessitates caution and monitoring due to the additive risk of Serotonin Syndrome. Concomitant use with anticoagulants (e.g., warfarin) or drugs affecting hemostasis (e.g., NSAIDs, aspirin) requires monitoring due to an increased risk of abnormal bleeding.

The official label mandates a 14-day separation period when switching between Celtium and MAOIs. Population-specific interaction notes specify that patients with hepatic impairment and individuals who are CYP2C19 poor metabolizers have reduced metabolic clearance, making them more susceptible to exposure-dependent interactions. The official documentation advises against alcohol use and notes that St. John's Wort may also increase the risk of Serotonin Syndrome and reduce Celtium exposure.

Mechanism of Action

How Celtium Works

The mechanism of action of Celtium is defined by its focused interaction with specific molecular targets. Celtium operates by selectively binding to and modulating the function of defined receptor or enzyme systems. This action is a regulatory event that results in the dampening of overactive physiological signaling within the primary pathways it engages.

Following this initial interaction, Celtium alters the dynamics of relevant signal transduction cascades. It either initiates or suppresses specific signaling sequences, which results in the restriction of excessive mediator activity and leads to defined physiological adjustments. By operating within these distinct mechanistic domains, this action establishes a more regulated state within the targeted pathways and contributes to the normalization of signaling dynamics.

Dosage and Administration Information

How to Use Celtium

Celtium (Escitalopram) is prescribed as an oral medication administered once daily. Standard usage guidelines define specific dosage parameters and procedural constraints for administration, ensuring consistent clinical practice.


Administration and Scheduling

Instruction Detail
Route of Administration Taken by mouth (oral). Available as coated tablets (5 mg, 10 mg, 20 mg) and an oral solution (1 mg/mL).
Frequency and Timing Administered once daily, and may be taken in the morning or evening, with or without food.
Standard Dosing (Adults) The initial recommended dose is 10 mg once daily. The maximum recommended dose for most adults is 20 mg once daily.
Dose Titration Any increase from 10 mg to 20 mg in adults should occur after a minimum treatment period of one week.

Population-Specific and Course Instructions

Administration guidelines include adjustments for specific patient groups and a defined procedure for ending treatment. The recommended daily dose for older adults (aged 65 years and older) and patients with hepatic impairment is typically limited to 10 mg. Adolescents (12–17 years) with Major Depressive Disorder (MDD) begin at 10 mg, with a maximum daily dose of 20 mg.

The course of treatment for MDD often requires maintenance for at least six months following response consolidation. Discontinuation of Celtium requires a gradual dose reduction process (tapering) rather than abrupt cessation. If a dose is missed, it is standard practice to skip the missed dose and continue with the next scheduled dose, without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celtium

Celtium's clinical evaluation has been explored through research to understand outcomes related to specific conditions. This overview describes the research framework, the outcomes studied, and the limits of the current evidence, based only on official and peer-reviewed scientific sources.


Evidence for Use in Major Depressive Disorder (MDD)

The research exploring outcomes related to MDD includes multiple short-term randomized controlled trials (RCTs). Studies have explored how symptoms change over time by tracking severity scores on standardized scales (like the MADRS). Research also monitored whether patients reached a stage of remission or achieved symptom response. In these acute trials, research describes patterns observed in the studies related to a reduction in high symptom intensity compared to placebo. Beyond the initial treatment phase, continuation studies were applied to examine the drug’s role in preventing the return of depressive episodes (relapse). This long-term research explored the maintenance of stability.

What remains largely uncertain is the measured outcome of treatment beyond one year. Long-term outcomes are not well characterized, as evidence from controlled trials primarily focuses on periods of up to 52 weeks. Additionally, study findings may not fully apply to people with certain complex medical conditions because those individuals are often excluded from the initial trials, meaning that data for these groups remain insufficient.


Evidence for Use in Generalized Anxiety Disorder (GAD)

Research exploring outcomes related to GAD includes multiple randomized controlled trials, typically over an 8- to 12-week period. These studies monitored outcomes reflecting daily functioning and the reduction of anxiety symptom intensity. Studies also explored whether continued treatment was associated with sustained stability over a longer duration. In these relapse prevention trials, research highlights changes measured during the study period related to the reporting of symptom recurrence in groups continuing treatment compared to groups who stopped.

The evidence base for GAD provides fewer systematic insights into the management of anxiety in children and young adolescents compared to adults. Furthermore, controlled studies focusing on people with GAD who also have other serious or unstable physical health conditions are limited, leading to a research gap regarding the outcomes in these specific, complex populations.


Evidence in Special Populations and Subgroups

Research has been conducted to understand the outcomes measured for Celtium in specific patient groups. Celtium was evaluated in studies involving adolescents aged 12 to 17 years who have MDD. Findings for older adults are generally derived from smaller studies, and the results apply only to the populations studied. The generalizability of these findings to all health profiles common in older age remains limited.


What Is Still Uncertain About Celtium’s Research Landscape

Despite the volume of data, the research surrounding Celtium still presents certain gaps. There is limited information for long-term outcomes that track patients for more than one year under controlled conditions. Furthermore, the evidence landscape lacks large-scale trials directly comparing Celtium against every other treatment option. Data for certain special groups, such as those with serious medical comorbidities or specific, complex psychiatric presentations, remain insufficient.

Key Studies & References

  1. Escitalopram: A systematic review of the efficacy and tolerability of a new molecular entity

Frequently Asked Questions (FAQ)

Common questions about Celtium (FAQ)

Q: How quickly does Celtium start working after you take it?

Studies indicate that symptom changes, such as improvements in sleep, energy, or appetite, may begin to be noticeable within the first 1 to 2 weeks of treatment. However, reaching the full benefit related to mood and interest may take up to 6 to 8 weeks of consistent use, based on the findings of clinical trials.

Q: Is Celtium considered a long-term or short-term medication?

Celtium is officially indicated for both the initial, short-term treatment of an episode and the long-term maintenance treatment of Major Depressive Disorder. The purpose of maintenance treatment is to help prevent the recurrence of symptoms, which may involve continued therapy for several months or longer, depending on the individual's treatment plan.

Q: Is there a generic version of Celtium available?

Yes, the active ingredient in Celtium, escitalopram, is widely available in generic formulations from various pharmaceutical manufacturers. This availability is confirmed by official product information.

Q: How is Celtium different from other similar medications?

Celtium belongs to the class of medications called Selective Serotonin Reuptake Inhibitors (SSRIs). Its active component, escitalopram, is the S-enantiomer of the older drug citalopram.

Q: Why do some people need to take Celtium for a long time?

Its primary purpose is to support maintenance treatment to help reduce the likelihood of recurrence or relapse of a depressive episode after initial improvement, a strategy informed by clinical research.

Q: Can older adults safely use Celtium?

Celtium can be used by older adults (aged 65 years and older), but official labeling advises a restricted maximum daily dosage. This caution is due to an increased risk of QTc prolongation—a heart rhythm abnormality—at higher doses in this population.

Q: Does the effectiveness of Celtium decrease over time (tolerance)?

Controlled clinical studies have demonstrated that continued treatment can help responsive patients maintain their stability and delay the time to relapse over many months. Official labeling suggests that the long-term usefulness of the medication requires periodic re-evaluation by a healthcare provider.

Q: Is it true that Celtium can affect your sleep patterns?

Yes, sleep-related changes are possible according to adverse reaction data from clinical trials. These changes include both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness or sleepiness).

Q: Is it common to feel tired when you first start taking Celtium?

Feeling tired or experiencing drowsiness, known as somnolence, is a common adverse reaction reported in clinical trials. Patients are encouraged to discuss any persistent or concerning side effects with their healthcare provider.

Q: What should I do if a side effect of Celtium is really bothersome?

Official patient counseling information advises reporting any bothersome side effects to a healthcare provider. This is important for proper management and monitoring of the treatment plan.

Q: Are there any natural supplements that interact with Celtium?

Regulatory information specifically advises against using St. John's Wort while taking Celtium. This herbal product may increase the risk of Serotonin Syndrome, a potentially serious condition. It is important for patients to discuss all herbal products and supplements they are using with their healthcare provider.

Q: What is the experience of stopping Celtium after long-term use?

Abrupt discontinuation, especially after long-term use, can lead to discontinuation symptoms such as dizziness, sensory disturbances, anxiety, and agitation. Official safety information advises that the dosage should be reduced gradually (tapering) under medical supervision to help minimize these symptoms.

Q: Can Celtium be split or crushed, or must it be swallowed whole?

Celtium is manufactured as coated tablets and is also available as a liquid oral solution. The oral solution provides an alternative option for patients who may find it difficult to swallow the tablets whole.

Q: What are the restrictions on driving or operating machinery while on Celtium?

Because Celtium has the potential to interfere with cognitive and motor skills, official information cautions individuals about driving or operating hazardous machinery until they know how the medication affects them.

Q: Does Celtium cause weight gain or weight loss?

In clinical trials, decreased appetite was noted as an adverse reaction. Official post-marketing experience reports have included observations of both weight gain and weight loss associated with the use of the medication.

Q: What is the maximum duration someone can safely take Celtium?

Systematic evidence from controlled trials on the long-term safety and usefulness primarily focuses on periods up to one year for maintenance purposes. For individual patients, the treating physician is advised to periodically re-evaluate the long-term benefit and necessity of continuing the drug.

Q: How long does Celtium stay in your system?

According to official pharmacokinetic data, the active substance, escitalopram, has an average elimination half-life of approximately 27 to 32 hours in adults. This is the time it takes for the concentration of the drug in the body to reduce by half.

Q: Can Celtium be taken with common over-the-counter pain relievers?

Caution is advised when Celtium is taken with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, or with aspirin. Official warnings note that this combination may increase the risk of bleeding.

Q: Does Celtium interact with caffeine or alcohol?

Official patient counseling information advises against the consumption of alcohol. There are no known interactions between Celtium and caffeine documented in the official regulatory labels.

Q: Is Celtium suitable for people who have difficulty swallowing pills?

Yes, to provide administration flexibility, Celtium is produced both as film-coated tablets and as a liquid oral solution. The oral solution is a useful alternative for those who may have trouble swallowing pills.

Q: Are there any known long-term effects of taking Celtium for many years?

Clinical evidence from controlled trials on the long-term effects and safety of Celtium is systematic up to one year. Any continuation of the medication beyond the period covered by systematic evidence is advised to include a periodic re-evaluation by a healthcare professional to assess the ongoing benefit.

Q: Does Celtium require regular monitoring (like blood tests)?

Official warnings indicate that monitoring is necessary for certain safety risks. This includes close observation for specific behavioral changes and checking for signs of low blood sodium (hyponatremia), which often involves blood tests.

Q: How does the body break down and eliminate Celtium?

The breakdown, or biotransformation, of the active ingredient occurs primarily in the liver. This metabolic process involves specific enzymes, such as CYP2C19, as detailed in the drug's pharmacokinetic profile.

How should Celtium be stored and disposed of?

Official Storage and Disposal Instructions

Celtium (Escitalopram) must be stored according to regulatory requirements to ensure its stability and effectiveness. The medication should be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), protected from excessive heat and moisture.

Storage Requirement Rule
Temperature Controlled Room Temperature
Protection Keep tightly closed; protect from moisture
Freezing Do not freeze the oral solution

The product must be kept in its original container and stored out of the sight and reach of children to prevent accidental ingestion. Unused or expired Celtium must be disposed of according to local regulations. The medicine should not be discarded via wastewater or household rubbish; authorized drug take-back programs must be utilized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celtium found in:

A-Z Index: